Karyopharm Therapeutics Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.53 | $-2.32 | -51.6% | Miss |
| Q12026 FY2026 | $-1.45 | $-1.24 | +14.5% | Beat |
Back to KPTI overview · KPTI holders · KPTI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.